{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017924","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.824180+00:00","generated_at":"2026-06-15T21:33:24.454447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND","bullets":["Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.","Cash, cash equivalents and marketable securities $73.0M as of March 31, 2023, projected to fund ops into Q3 2024.","Nominated first herpesvirus candidate ABI-5366; plans to enter clinic first half 2024; expects additional candidate nomination in 2023.","Evaluating partnering options for core HBV inhibitor portfolio to focus on expanded virology programs.","Multiple abstracts accepted for presentation at EASL 2023 in June for HBV/HDV entry inhibitor and core inhibitor data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017924","json":"https://secwatch.observer/filing/0000950170-23-017924.json","markdown":"https://secwatch.observer/filing/0000950170-23-017924.md","text":"https://secwatch.observer/filing/0000950170-23-017924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/0000950170-23-017924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/asmb-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:33:24.454447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1632442b1cb5ee96d1104c1d9f72e2a492f873dc","claim":"ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: net income $19.0 million, EPS $0.37 per basic and diluted share.","evidence_excerpt":"Net loss attributable to common stockholders was $19.0 million, or $0.37 per basic and diluted share, for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/0000950170-23-017924-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$19.0 million"},{"label":"EPS","value":"$0.37 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}